Pharmacogenetics and pharmacogenomics of anticancer agents

CA Cancer Journal for Clinicians

Volumn 59, Issue 1, 2009, Pages 42-55

  Huang, R Stephanie ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; AROMATASE INHIBITOR; CAPECITABINE; FLUOROURACIL; IRINOTECAN; MERCAPTOPURINE; TAMOXIFEN;

BLOOD TOXICITY; BREAST CANCER; CANCER THERAPY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CLEARANCE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE IDENTIFICATION; GENE REPLICATION; GENETIC MARKER; GENETIC SCREENING; GENETIC VARIABILITY; GENETICS; GENOMICS; GENOTYPE; HEALTH CARE PERSONNEL; HERITABILITY; HORMONAL THERAPY; HUMAN; LEUKOPENIA; LUNG CANCER; MEDICAL EDUCATION; MEDICAL TECHNOLOGY; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; VALIDATION PROCESS;

6-MERCAPTOPURINE; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FLUOROURACIL; GENETIC MARKERS; GENOME, HUMAN; GENOTYPE; HUMANS; NEOPLASMS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; TAMOXIFEN;

EID: 58849149494     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.20002     Document Type: Review

References (110)

1. Adverse Drug Events: The Magnitude of Health Risk is Uncertain Because of Limited Incidence Data. Washington, DC: US General Accounting Office; 2000.
2. Bates D, Gawande A. Error in medicine: what have we learned? Ann Intern Med. 2000;132:763-767.
3. Meyer UA. Pharmacogenetics-5 decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004;6:669-676.
4. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;12:1294-1300.
5. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res. 2005;11:1534-1538.
6. Hoskins J, Goldberg R, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007;99:1290-1295.
7. Griffiths AJ, Miller JH, Suzuki DT, et al. An Introduction to Genetic Analysis. New York: W.H. Freeman and Co.; 1996.
8. Oroszi G, Goldman D. Alcoholism: genes and mechanisms. Pharmacogenomics. 2004;5:1037-1048.
9. Schnoll R, Johnson T, Lerman C. Genetics and smoking behavior. Curr Psychiatry Rep. 2007;9:349-357.
10. Faraday N, Yanek L, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation. 2007;115:2490-2496.
11. Luciano M, Zhu G, Kirk K, et al. "No thanks, it keeps me awake": the genetics of coffee-attributed sleep disturbance. Sleep. 2007;30:1378-1386.
12. Cloos J, Nieuwenhuis E, Boomsma D, et al. Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst. 1999;91:1125-1130.
13. Dolan ME, Newbold KG, Nagasubramanian R, et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004;64:4353-4356.
14. Watters JW, Kraja A, Meucci MA, et al. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A. 2004;101:11809-11814.
15. Duan S, Bleibel W, Huang R, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 2007;67:5425-5433.
16. Bosch T, Meijerman I, Beijnen J, Schellens J. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet. 2006;45:253-285.
17. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther. 2005;107:155-176.
18. US Department of Energy Office of Science, Office of Biological and Environmental Research, and Human Genome Program. Human Genome Project Information. Available at: http://www.ornl.gov/sci/techresources/Human-Genome/ home.shtml. Accessed May 21, 2008.
19. International HapMap Project. About the HapMap. Available at: http://www.hapmap.org/thehapmap.html.en. Accessed May 30th, 2008.
20. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of 7 common diseases and 3,000 shared controls. Nature. 2007;447:661-678.
21. Forbes S, Clements J, Dawson E, et al. COSMIC 2005. Br J Cancer. 2006;94:318-322.
22. Huang RS, Duan S, Bleibel WK, et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007;104:9758-9763.
23. Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007;81:427-437.
24. Thomas G, Jacobs K, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40:310-315.
25. Sklar P, Smoller J, Fan J, et al. Whole-genome association study of bipolar disorder. Mol Psychiatry. 2008;13:558-569.
26. Tomlinson I, Webb E, Carvajal-Carmona L, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet. 2008;40:623-630.
27. Ratain MJ. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res. 2006;12:1658-1660.
28. Roche Dianostics. AmpliChip. Available at: http://www.amplichip.us/index. php. Accessed May 30, 2008.
29. 23andMe Inc. 23andMe genetics just got personal. Available at: https://www.23andme.com/. Accessed May 30, 2008.
30. Pagon RA, Terry E, Espeseth M, et al. GeneTests. Available at: http://www.genetests.org/. Accessed May 30, 2008.
31. Holleman A, Cheok M, den Boer M, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-542.
32. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312.
33. Weinshilboum R, Sladek S. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
34. Gorski J, Hall S, Jones D, et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994;47:1643-1653.
35. Chiou W, Jeong H, Wu T, Ma C. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin Pharmacol Ther. 2001;70:305-310.
36. Riegert-Johnson D, Macaya D, Hefferon T, Boardman L. The incidence of duplicate genetic testing. Genet Med. 2008;10:114-116.
37. International HapMap Consortium, Frazer K, Ballinger D, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851-861.
38. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
39. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
40. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23:9312-9318.
41. Goetz MP, Suman VJ, Ingle JN, et al. A 2-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006;12(7 pt 1):2080-2087.
42. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30-39.
43. Massarweh S, Osborne C, Creighton C, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008;68:826-833.
44. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119-137.
45. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmaco-epigenetic and clinical aspects. Pharmacol Ther. 2007;116:496-526.
46. Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93-101.
47. Clarke R, Liu M, Bouker K, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003;22:7316-7339.
48. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol. 1977;76:305-316.
49. Goetz M, Knox S, Suman V, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113-121.
50. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25:5187-5193.
51. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008;99:995-999.
52. Desta Z, Flockhart D. Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol. 2007;25:5147-5149.
53. Gaedigk A, Simon S, Pearce R, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234-242.
54. DNAdirect. DNAdirect. Your Genes. Your Health. Your Choices. Available at: http://www.dnadirect.com/. Accessed May 30, 2008.
55. Punglia R, Burstein H, Winer E, Weeks J. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008;100:642-648.
56. Gjerde J, Hauglid M, Breilid H, et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol. 2008;19:56-61.
57. Wegman P, Elingarami S, Carstensen J, et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 2007;9:R7.
58. Lim Y, Li L, Desta Z, et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther. 2006;318:503-512.
59. Petros W, Evans WE. Pharmacogenomics in cancer therapy: is host genome variability important? Trends Pharmacol Sci. 2004;25:457-464.
60. Yong W, Innocenti F. Translation of pharmacogenetic knowledge into cancer therapeutics. Clin Adv Hematol Oncol. 2007;5:698-706.
61. Lennard L, Lilleyman J, Loon JV, Weinshilboum R. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225-229.
62. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA. 2005;293:1485-1489.
63. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics. 2002;3:89-98.
64. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14:407-417.
65. van den Akker-van Marle M, Gurwitz D, Detmar S, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics. 2006;7:783-792.
66. Hartford C, Dolan M. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics. 2007;8:1159-1168.
67. Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol. 2006;1:119-128.
68. Givens RC, Watkins PB. Pharmacogenetics and clinical gastroenterology. Gastroenterology. 2003;125:240-248.
69. Maitland M, Vasisht K, Ratain M. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006;27:432-437.
70. Rothenberg M. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol. 1998;25(5 suppl 11):39-46.
71. Iyer L, King C, Whitington P, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101:847-854.
72. Carlini L, Meropol N, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/ irinotecan. Clin Cancer Res. 2005;11:1226-1236.
73. Han J, Lim H, Shin E, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006;24:2237-2244.
74. Innocenti F, Liu W, Chen P, et al. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics. 2005;15:295-301.
75. de Jong F, Scott-Horton T, Kroetz D, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007;81:42-49.
76. Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics. 2003;13:741-757.
77. Zhou Q, Sparreboom A, Tan E, et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol. 2005;59:415-424.
78. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171-1175.
79. Hasegawa Y, Sarashina T, Ando M, et al. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin Chem. 2004;50:1479-1480.
80. Meyerhardt J, Kwok A, Ratain M, et al. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:1439-1446.
81. Baudhuin L, Highsmith W, Skierka J, et al. Comparison of 3 methods for genotyping the UGT1A1 (TA)n repeat polymorphism. Clin Biochem. 2007;40:710-717.
82. Schwab M, Zanger U, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26:2131-2138.
83. [no authors listed] Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol. 1998;16:3537-3541.
84. Diasio R, Beavers T, Carpenter J. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988;81:47-51.
85. Etienne M, Lagrange J, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994;12:2248-2253.
86. Fleming R, Milano G, Thyss A, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52:2899-2902.
87. Lu Z, Zhang R, Diasio R. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993;53:5433-5438.
88. Okuda H, Nishiyama T, Ogura K, et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos. 1997;25:270-273.
89. Ceppi P, Volante M, Ferrero A, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res. 2008;14:1059-1064.
90. Kuo S, Wang H, Chow K, et al. Expression of rTSbeta as a 5-fluorouracil resistance marker in patients with primary breast cancer. Oncol Rep. 2008;19:881-888.
91. Milano G, Etienne M, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10:1171-1175.
92. Port R, Daniel B, Ding R, Herrmann R. Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. Oncology. 1991;48:277-281.
93. Chansky K, Benedetti J, Macdonald J. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103:1165-1171.
94. Sloan J, Goldberg R, Sargent D, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20:1491-1498.
95. Wei X, Elizondo G, Sapone A, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 1998;51:391-400.
96. Van Kuilenburg A, Meinsma R, Zoetekouw L, Van Gennip A. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer. 2002;101:253-258.
97. Yen J, McLeod H. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. 2007;43:1011-1016.
98. Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs. 2005;23:533-537.
99. Etienne-Grimaldi M, Francoual M, Formento J, Milano G. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics. 2007;8:1561-1566.
100. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5:2895-2904.
101. Lecomte T, Ferraz J, Zinzindohoüé F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res. 2004;10:5880-5888.
102. Ichikawa W, Takahashi T, Suto K, et al. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res. 2006;12:3928-3934.
103. Pullarkat S, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1:65-70.
104. Wheeler DA, Srinivasan M, Egholm M, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature. 2008;452:872-877.
105. Levy S, Sutton G, Ng P, et al. The diploid genome sequence of an individual human. PLoS Biol. 2007;5:e254-e286.
106. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006;25:1679-1691.
107. SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359:789-799.
108. Christensen K, Murray JC. What genomewide association studies can do for medicine. N Engl J Med. 2007;356:1094-1097.
109. Obama B. The genomics and Personalized Medicine Act of 2006. Clin Adv Hematol Oncol. 2007;5:39-40.
110. Lesko L, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov. 2004;3:763-769.